Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
On January 27, Citi modestly cut its price target on AbbVie Inc. (NYSE:ABBV) to $230 from $235 while leaving its Neutral rating unchanged. The adjustment was part of the firm's broader Q4 review of the biopharma space. In its note, Citi said expectations across the sector look manageable, with earnings that could come in better than feared, and added that lower policy-related risk could create a more supportive backdrop for the group in 2026. At the same time, AbbVie faced some disappointing clinical news. According to a January 16 Reuters report, AbbVie and its partner Genmab said their blood cancer drug epcoritamab failed to show a clear survival benefit in a late-stage study. The trial enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma who had already been treated at least once and were not eligible for intensive chemotherapy followed by a stem cell transplant. While patients on the drug did not live longer in a statistically meaningful way at the
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform [Yahoo! Finance]Yahoo! Finance
- AbbVie (NYSE:ABBV) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
- AbbVie sues US health agency over Botox price controls [Yahoo! Finance Canada]Yahoo! Finance Canada
- AbbVie (NYSE:ABBV) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.MarketBeat
- AbbVie (NYSE:ABBV) was given a new $230.00 price target on by analysts at UBS Group AG.MarketBeat
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 2/4/26 - Form 8-K
- 1/7/26 - Form 8-K
- 1/5/26 - Form 4
- ABBV's page on the SEC website